Asia is the world's most populous region for transfusion-dependent thalassemia and SCD - driving substantial demand for oral iron chelation. This guide maps the regulatory landscape and sourcing considerations across the continent.
1. ASEAN Markets (ACTD) #
ASEAN countries largely accept the ASEAN Common Technical Dossier (ACTD) - Parts I-IV mapping closely to CTD Modules. Harmonisation reduces duplication but each country still has its own Module 1 requirements and submission timelines.
- Philippines (FDA-PH)
- Vietnam (Drug Administration of Vietnam - DAV)
- Malaysia (NPRA)
- Indonesia (BPOM)
- Thailand (Thai FDA)
- Singapore (HSA)
2. GCC Markets #
Gulf Cooperation Council countries operate a partially harmonised central registration (SFDA as anchor) plus national registrations:
- Saudi Arabia (SFDA)
- UAE (MoHAP / DHA / DOH)
- Kuwait, Qatar, Bahrain, Oman
3. South Asian Markets #
- India (CDSCO) - both source and destination
- Bangladesh (DGDA)
- Pakistan (DRAP)
- Sri Lanka (NMRA)
- Nepal (DDA)
4. Key Sourcing Considerations #
- WHO-GMP certificate with dispersible-tablet scope
- Stability per climatic zone (most of Asia is IVb)
- Language capability (Arabic, Bahasa, Vietnamese, Urdu, etc.)
- Competitive pricing given the region's substantial patient volumes
- Reliable lead times from India (10-18 day sea transit typical)
5. Channel Considerations #
Asia channels vary from large public-sector tenders (Indonesia government procurement, Philippine DOH) to organised private specialty pharmacy networks (GCC) to donor-funded programmes (selected South Asian contexts).
6. Taj Pharma in Asia #
DEFRATAJ is supplied across ACTD, GCC and South Asian markets through registered distributors. See Vietnam and Philippines landers.